Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes To the Editor: Combination therapy with oral clindamycin, 300 mg twice daily, plus rifampicin, 300 mg twice daily or 600 mg once daily, for 10 weeks is among the keystone treatments for moderate-to-severe hidradenitis suppurativa (HS).
1 Since 2006, 6 small studies involving a total of 178 patients have investigated the efficacy of this antibiotic combination. [2] [3] [4] Most of the studies had a retrospective design, and only 1 reported safety outcomes. 4 The prevalence of treatment interruption ranged from 9.1% to 28.6% (mean, 16.3%), and the rate of appearance of adverse events ranged from 9.1% to 38.3% (mean, 21.9%). [2] [3] [4] The most common adverse events were gastrointestinal (GI) disturbances (diarrhea, vomiting, abdominal pain, and dyspepsia), followed by cutaneous rash, vaginitis, nonspecific pain, and arthralgia.
A better understanding of the reasons for poor adherence and adverse events associated with treatment may help dermatologists to better advise patients, potentially allowing prevention of some side effects.
We designed a descriptive, observational, retrospective multicentric study to determine the prevalence of interruption of clindamycin plus rifampicin before 10 weeks in patients with HS. A retrospective chart review was performed; included were patients who were at least 18 years old, had Hurley stage II or III HS, and were receiving clindamycin plus rifampicin for the first time. Patients simultaneously receiving other systemic therapies for HS were excluded.
We enrolled 509 patients from 14 Spanish hospitals (Table I) ; 135 of them (26.5%) interrupted antibiotic treatment. We did not observe differences between the proportions of men (26.6%) and women (26.5%) who interrupted their treatment. After dividing the study population into quartiles by age (#30 years, n ¼ 133; 31-38 years, n ¼ 127; 39-49 years, n ¼ 125; and $50 years, n ¼ 124), we observed that older age was associated with interruption of treatment. The odds ratio (OR) for treatment interruption in patients aged 50 or older versus patients in the youngest age group was 1.9 (95% confidence interval [CI], 1.1-3.3; P ¼ .03). Ever-smokers had 1.5 times the odds of interrupting their treatment as compared with never-smokers (95% CI, 1.1-2.1; P ¼ .02). In multivariable analysis, these associations remained significant ( for smoking: OR, 1.7; 95% CI, 1.0-2.7; P ¼ .033; for age $50: OR, 1.8; 95% CI, 1.0-2.7; P ¼ .048).
We did not observe any association between treatment interruption and any other feature (Table II) . There were 182 adverse effects in In conclusion, to our knowledge, this is the largest reported series of patients treated with a combination of clindamycin plus rifampicin for HS. We observed higher rates of treatment interruption and prevalence of adverse effects than previously reported. Patients aged 50 years or older and smokers were more prone to interrupt their treatment. GI disturbances were the most frequent adverse effects in our population. Physicians may consider prescribing probiotics to these patients at higher risk of GI side effects. 
